2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Pituitary ACTH Hypersecretion: new trials by email Literature Review of Pituitary ACTH Hypersecretion trials Research Report on Pituitary ACTH Hypersecretion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) rosiglitazone maleate - Cushing's Disease | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 2 | 2007-04-01 | 2020-08-06 |
Adrenocortical Hyperfunction (1) · Pituitary Neoplasms (1)
Brain Diseases (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Hyperpituitarism (2) · Hypothalamic Diseases (2) · Nervous System Diseases (2) · Pituitary Diseases (2) · Adrenal Gland Diseases (1) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Hypothalamic Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Neoplasms (1)
Cabergoline (1) · Rosiglitazone (1) · pasireotide (1)
Jonsson Comprehensive Cancer Center (1) · Novartis Pharmaceuticals (1)
United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · Colombia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Italy (1) · Malaysia (1) · Mexico (1) · Netherlands (1) · Spain (1)